CD274 and prostate neoplasm: Potluri et al. demonstrated that 90Y-NM600 was selectively retained within TRAMP-C1 and Myc-CaP murine prostate tumors and, while it exhibited modest anti-tumor efficacy itself, treatment led to increased expression of PD-L1 by these tumors [120].